Spots Global Cancer Trial Database for mzl
Every month we try and update this database with for mzl cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732926 | Indolent Non-Ho... | Idelalisib Rituximab Bendamustine Placebo | 18 Years - | Gilead Sciences | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732913 | Indolent Non-Ho... | Placebo Rituximab Idelalisib | 18 Years - | Gilead Sciences | |
| First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 | NCT05737628 | Lymphoma | BYON4228 + Ritu... | 18 Years - | Byondis B.V. | |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | NCT04043845 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... | Ibrutinib LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma | NCT02180711 | Non Hodgkin Lym... | acalabrutinib rituximab (IV) Lenalidomide | 18 Years - | Acerta Pharma BV | |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | NCT05828589 | Relapsed Non-Ho... Refractory Non-... Relapsed Chroni... Refractory Chro... Relapsed Follic... Relapsed Margin... Relapse Diffuse... Relapsed Small ... Refractory Foll... Refractory Marg... Refractory Smal... Richter Transfo... Refractory Diff... Transformed Non... | BGB-21447 | 18 Years - | BeiGene | |
| Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma | NCT03846427 | Marginal Zone L... MZL | Zanubrutinib | 18 Years - | BeiGene | |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | NCT04043845 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... | Ibrutinib LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | NCT05828589 | Relapsed Non-Ho... Refractory Non-... Relapsed Chroni... Refractory Chro... Relapsed Follic... Relapsed Margin... Relapse Diffuse... Relapsed Small ... Refractory Foll... Refractory Marg... Refractory Smal... Richter Transfo... Refractory Diff... Transformed Non... | BGB-21447 | 18 Years - | BeiGene | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma | NCT04431089 | Follicular Lymp... Marginal Zone L... | SHC014748M | 18 Years - | Nanjing Sanhome Pharmaceutical, Co., Ltd. | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated | NCT03888105 | B-cell Non-Hodg... | Odronextamab | 18 Years - | Regeneron Pharmaceuticals | |
| Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | NCT03786926 | Lymphoma | HMPL-689 | 18 Years - | Hutchmed | |
| A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) | NCT03797456 | MZL | ICP-022 | 18 Years - 75 Years | Beijing InnoCare Pharma Tech Co., Ltd. | |
| Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma | NCT00453102 | Marginal Zone L... | Rituximab Ibritumomab Tiu... | 18 Years - 120 Years | University of Miami | |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma | NCT02793583 | Diffuse Large B... Follicular Lymp... Marginal Zone L... Mantle Cell Lym... Small Lymphocyt... | Ublituximab Umbralisib Bendamustine | 18 Years - | TG Therapeutics, Inc. | |
| Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma | NCT04903197 | Non-Hodgkin Lym... | VAY736 lenalidomide | 18 Years - | Novartis | |
| Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies | NCT04277637 | Mature B-Cell M... | BGB-11417 Zanubrutinib obinutuzumab | 18 Years - | BeiGene | |
| A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | NCT03893682 | Chronic Lymphoc... Small Lymphocyt... Non-Hodgkin's L... | CG-806 | 18 Years - | Aptose Biosciences Inc. | |
| First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 | NCT05737628 | Lymphoma | BYON4228 + Ritu... | 18 Years - | Byondis B.V. | |
| Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma | NCT01980628 | Marginal Zone L... B-cell Lymphoma | ibrutinib | 18 Years - | Pharmacyclics LLC. | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | NCT03328078 | Relapsed Hemato... Refractory Hema... Relapsed Primar... Refractory Prim... | Emavusertib ibrutinib | 18 Years - | Curis, Inc. | |
| A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated | NCT03888105 | B-cell Non-Hodg... | Odronextamab | 18 Years - | Regeneron Pharmaceuticals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
